Azitra reported repeat-dose ex vivo delivery of rHDfilaggrin into the stratum granulosum and dose-dependent increases in skin elasticity.
Key Highlights:
- Issued press release reporting two ex vivo human skin studies for ATR-COSF demonstrating improved distribution and anti-wrinkle activity.
- Repeat-dose 2% lyophilized supernatant hydrogel showed increased rHDfilaggrin delivery into stratum corneum and stratum granulosum versus single dose.
- Formulated product delivered higher concentrations to target layers than concentrated supernatant alone, suggesting formulation benefit.
- Hydrogel with lyophilized supernatant increased ex vivo skin elasticity dose-dependently (0.09% = 1.6x; 7.5% = 4.4x), 0.28% restored elasticity to healthy skin benchmarks.
- 2% formulation tested non-irritating and non-corrosive in standardized safety assays; company plans further formulation optimization and human study design.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.